Mesalazine for diverticular disease of the colon - A new role for an old drug

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 1, 2005, Pages 69-74

  Tursi, Antonio ^a,b  

^a Digestive Endoscopy Unit   (Italy)

^b NONE   (Italy)

Author keywords

Antibiotic therapy; Diverticulitis; Mesalazine; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BALSALAZIDE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; OLSALAZINE; PROBIOTIC AGENT; RIFAXIMIN; SALICYLIC ACID DERIVATIVE; SULTAMICILLIN;

ACUTE DISEASE; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COLON DIVERTICULOSIS; DEFECATION; DEVELOPED COUNTRY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG MECHANISM; DRUG POTENTIATION; ENTERITIS; HUMAN; NEPHROTOXICITY; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SYMPTOMATOLOGY; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIVERTICULITIS, COLONIC; DRUG THERAPY, COMBINATION; HUMANS; MESALAMINE; RIFAMYCINS;

EID: 12844287441     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.1.69     Document Type: Review

References (43)

1. PARKS TG: Natural history of diverticular disease of the colon. Clin. Gastroenterol. (1974) 4:53-69.
2. BOLES RS Jr, JORDAN SM: The clinical significance of diverticulosis. Gastroenterology (1958) 35:579-582.
3. AYDIN HN, REMZI FH: Diverticulitis: when and how to operate? Digest. Liver Dis. (2004) 36:435-445.
4. BERMAN LG, BURDICK D, HEITZMAN ER, PRIOR JT. A critical reappraisal of sigmoid peridiverticulitis. Surg. Gyn. Obstet. (1968) 127:481-491.
5. FLOCH M, BINA I: The natural history of diverticulitis - fact and theory. J. Clin. Gastroenterol. (2004) 38(Suppl. 1):S2-S7.
6. KOHLER L, SAUERLAND S, NEUGEBAUER E: Diagnosis and treatment of diverticular disease: result of a Consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg. Endosc. (1999) 13:430-436.
7. TURSI A. Acute diverticulitis of the colon - current medical therapeutic management. Expert Opin. Pharmacother. (2004) 5 145-149.
8. SCHECHTER S, MULVEY J, EISENSTAT TE: Management of uncomplicated acute diverticulitis: results of a survey. Dis. Colon Rectum (1999) 42:470-476.
9. FERZOCO LB, RAPTOPOULOS V, SILEN W: Acute diverticulitis. N. Engl. J. Med. (1998) 338:1521-1526.
10. LAMANNA A, ORSI A: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemiaterapia (1984) 11:365-367.
11. PAPI C, CIACO A, KOCH M, CAPURSO L: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. (1995) 9:33-39.
12. LATELLA G, PIMPO MT, SOTTILI S et al.: Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int. J. Colorectal Dis. (2003) 18:55-62.
13. HANAUER SB: Medical Therapy for ulcerative colitis 2004. Gastroenterology (2004) 126:1582-1592.
14. SANDBORN WJ, HANAUER SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 17:29-42.
15. ELIAKIM R, RACHMILEWITZ D: Potential mediators in inflammatory bowel disease. Gastroenterology Int. (1992) 5 48-56.
16. GRISHAM MB: Oxidants and free radicals in inflammatory bowel disease. Lancet (1994) 344:859-861.
17. WOOD AJJ: Inflammatory bowel disease. N. Engl. J. Med. (1996) 334:841-848.
18. GONÇALVES E, ALMEIDA LM, DINIS TC: Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Rad. Res. (1998) 29:53-66.
19. RAMPTON DS: Diverticular colitis: diagnosis and management. Colorectal Disease (2001) 3:149-153.
20. LUDEMAN L, SHEPERD NA: What is diverticular colitis? Pathology (2002) 34:568-572.
21. KELLY JK: Polypoid prolapsing mucosal folds in diverticular disease. Am. J. Surg. Pathol. (1991) 15:871-878.
22. SHEPERD NA. Colorectal submucosal mass lesions masquerading as chronic inflammatory bowel disease on mucosal biopsy. J. Pathol. (1995) 175:119A.
23. GUSLANDI M: Segmental colitis: so what? Eur. J. Gastroenterol. Hepatol.(2003) 15:1-2.
24. ROGLER G, ANDUS T: Cytokins in inflammatory bowel disease. World J. Surg. (1998) 22:382-389.
25. IZZO AA, MASCOLO N, CAPASSO F: Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig. Dis. Sci. (1998) 43:1605-1620.
26. TRESPI E, COLLA C, PANIZZA P et al.: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results. Minerva Gastroenterol. Dietol. (1999) 45:245-252.
27. GIOVANNI A, LEANDRO G, FANIGLIULO M et al.: Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Digest. Liver Dis. (2004) 36(Suppl. 2):S189.
28. BRANDIMARTE G, TURSI A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med. Sci. Monit. (2004) 10:170-173.
29. TURSI A, BRANDIMARTE G, DAFFINÀR: Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Digest. Liver. Dis. (2002) 34:510-515.
30. BASSOTTI G, CHISTOLINI F, MORELLI A: Pathophysiological aspect of diverticular disease of colon and role of large bowel motility. World J. Gastroenterol. (2003) 9:2140-2142.
31. TURSI A, BRANDIMARTE G, GIORGETTI GM, NASI G: Assessment of orocecal transit time in different localisation of Crohn's disease and its possibile influence on clinical response to therapy. Eur. J. Gastroenterol. Hepatol. (2003) 15:69-74.
32. SCHEIBER S, HAMLING J, ZEHNTER E et al.: Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut (1997) 40:761-766.
33. KRUIS W, SCHREIBER S, THEUER D et al.: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsazide (3.0 g twice daily) was superior in preventing relapses. Gut (2001) 49 738-739.
34. LEVINE DS, RIFF DS, PRUITT R et al.: A randomized, double blind, dose response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:1398-1407.
35. PRUITT R, HANSON J, SAFDI M et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:3078-3086.
36. SANDERS ME: Probiotics. Food Technol. (1999) 53 67-77.
37. GIACCARI S, TRONCI S, FALCONIERI M, FERRIERI A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur. Rev. Med. Pharmacol. Sci. (1993) 15:29-34.
38. FRI P, ZAVORAL M: The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur. J. Gastroenterol. Hepatol. (2003) 15:313-315.
39. DWIVEDI A, CHAHIN F, AGRAWAL S et al.: Laparoscopic colectomy versus open colectomy for sigmoid diverticular disease. Dis. Colon Rectum (2002) 45:1309-1314.
40. DUGAS B, MERCENIER A, LENOIR-WIJNKOOP I, ARNAUD C, DUGAS N, POSTAIRE E: Immunity and probiotics. Immunol. Today (1999) 20 387-390.
41. BENGMARK S: Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut (1998) 42:2-7.
42. GIONCHETTI P, RIZZELLO F, CIFONE G et al.: In vivo effect of a highly concentrated probiotic on IL-10 pelvic pouch tissue levels. Gastroenterology (1999) 116:A723.
43. GIONCHETTI P, AMADINI C, RIZZELLO F et al.: Probiotics - role in inflammatory bowel disease. Digest. Liver. Dis. (2002) 34(Suppl. 2):S58-S62.